New Oral Drug Sotyktu for Plaque Psoriasis Patients Demonstrates Promising Results with Favorable Safety Profile

According to Professor Enikö Sonkoly, the POETYK2 STUDY received a great deal of attention at EADV2023, as several presentations and posters reviewed the efficacy and safety of deucravacitinib, a new oral drug for the treatment of chronic plaque psoriasis. In this MEDtalk, she elaborates on the findings from the study and explains the mechanisms of the TYK2 inhibitor.